

1st Alpine Winter Conference on Medicinal and Synthetic Chemistry

Confirmed Speakers

Keynote Speakers

KL01 - Recent Developments in Strategies and Tactics Towards the Synthesis of Complex Secondary Metabolites as Enabling Tools for the Study of Biology and Medicine



Erick M. CARREIRA
(ETH ZÜRICH, Zürich, Switzerland)

KL02 - Activity-based proteomics – Protein and Ligand Discovery on a Global Scale



Benjamin CRAVATT
(THE SCRIPPS RESEARCH INSTITUTE, La Jolla, United States)

KL03 - Novel Approaches in the Design of CNS Drug Candidates and PET Ligands



Anabella VILLALOBOS
(BIOGEN, Cambridge, United States)

Addressing Preclinical Toxicity – Approaches and Lessons Learned

PL06 - Reducing Bioactivation Potential of Drug Candidates: Implications for Preclinical Drug Optimization



Andreas BRINK
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

PL04 - Mechanism-Based Toxicities Associated With NAMPT Inhibition and Related Mitigation Strategies



Peter DRAGOVICH
(GENENTECH INC., San Francisco, United States)

OC02 - Small Structural Changes Leading to Major Impact on Safety: Developing Safety Strategies in Medicinal Chemistry



Martin PETTERSSON
(PFIZER, Cambridge, United States)

PL05 - Utilizing in Depth Understanding of a Molecules Off-Target Profile to Tailor Clinical and Preclinical Safety Assessments



Douglas THOMSON
(CELLZOME GMBH, Heidelberg, Germany)

Advances in Lead Generation

PL08 - A Chemist's Guide to Modern Phenotypic Drug Discovery

1st Alpine Winter Conference on Medicinal and Synthetic Chemistry

Confirmed Speakers



Monika ERMANN
(EVOTEC LTD, Oxfordshire, United Kingdom)

OC03 - CDK8 Inhibitors with Pre-Engineered Long Residence Time, Exhibiting Efficacy in Tumor Xenograft Models



Koen HEKKING
(MERCACHEM-SYNCOM, Nijmegen, The Netherlands)

PL07 - ADAS (Affinity Directed Automated Synthesis): A New Technology to Accelerate Lead Generation



Eva Maria MARTIN
(ELI LILLY, Madrid, Spain)

PL09 - From Multiple Hit Series to (Pre)Clinical Candidates Using DNA-Encoded Library Technology



Sanne SCHRODER GLAD
(NUEVOLUTION A/S, Copenhagen, Denmark)

Advances in Synthetic Methods

PL01 - Assembly Line Synthesis



Varinder K. AGGARWAL
(UNIVERSITY OF BRISTOL, Bristol, United Kingdom)

PL02 - Photochemical Reactions en route to Structurally Complex Molecules



Thorsten BACH
(TECHNISCHE UNIVERSITÄT MÜNCHEN, Garching, Germany)

PL03 - Expanding the Potential of Organocatalysis with Light



Paolo MELCHIORRE
(INSTITUTE OF CHEMICAL RESEARCH OF CATALONIA (ICIQ), Bologna, Italy)

OC01 - Exploring 3-D Pharmaceutical Space: New CH Functionalisation Reactions of Oxygen and Sulfur Heterocycles



Peter O'BRIEN
(UNIVERSITY OF YORK, York, United Kingdom)

Alternative Modalities

OC05 - Proteolysis Targeting Chimera: A New Frontier in Medicinal Chemistry

1st Alpine Winter Conference on Medicinal and Synthetic Chemistry

Confirmed Speakers



Niall ANDERSON
(GLAXOSMITHKLINE, Hertfordshire, United Kingdom)

PL13 - Messenger RNA as a Novel Therapeutic Approach



Kerry BENENATO
(MODERNA THERAPEUTICS, Cambridge, United States)

PL11 - Intracellular Delivery of Macromolecules



David TELLERS
(MERCK & CO. INC (MSD), West Point, United States)

PL12 - New Modalities Probe and Hit Finding for Challenging Targets in Cardiovascular and Metabolic Diseases



Eric VALEUR
(ASTRAZENECA, IMED BIOTECH UNIT, Cambridge, United States)

Challenges and Opportunities in Fragment Based Drug Discovery

OC07 - Fragment-Centric Methodologies for the Discovery of DOT1L Inhibitors



Christoph GAUL
(NOVARTIS, Basel, Switzerland)

OC12 - Rational Design of Small-Molecules Inhibitors of Human Cyclophilins with a Pan Viral Activities by Fragment Based Drug Design Using a Linking Strategy



Jean-Francois GUICHOU
(CBS INSERM U1054, Montpellier, France)

PL17 - Drug Discovery for Challenging Targets by X-ray Crystallographic Fragment Screening



Tom HEIGHTMAN
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom)

PL18 - The Impact of Fragments on Drug Discovery



Rod HUBBARD
(UNIVERSITY OF YORK & VERNALIS, Cambridge, United Kingdom)

Chemical Biology in Drug and Target Discovery

OC04 - Chemical Physiology of Antibody Conjugates and Natural Products

1st Alpine Winter Conference on Medicinal and Synthetic Chemistry

Confirmed Speakers



Gonçalo BERNARDES
(INSTITUTO DE MEDICINA MOLECULAR, PORTUGAL & UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

PL10 - Fluorescent and Bioluminescent Sensor Proteins



Kai JOHNSON
(MAX-PLANCK INSTITUTE FOR MEDICAL RESEARCH, Heidelberg, Germany)

Late Stage Functionalization

PL15 - The Quest for Efficient Ligands in Asymmetric C-H Functionalizations



Nicolai CRAMER
(ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE, Lausanne, Switzerland)

PL16 - Catalytic Approaches to Simplifying Synthesis



Darren J. DIXON
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

PL14 - New Chemical Tools for the Late Stage Functionalization of Biomolecules



Matthew GAUNT
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

OC06 - Synthetic Routes to Oxindoles via Metal Catalysis



Mark LAUTENS
(UNIVERSITY OF TORONTO, Toronto, ON, Canada)

Drug Discovery Tales

OC10 - Molecular Accessibility - Measuring and Understanding the Intracellular Free Concentration of Drugs During Lead Optimisation

(EYEDPHARMA)

OC09 - Discovery of Tak-041: A Potent and Selective Gpr139 Agonist for the Treatment of Negative Symptoms Associated with Schizophrenia



Holger MONENSCHEN
(TAKEDA CALIFORNIA, INC, San Diego, United States)

OC08 - Discovery of Allosteric Malt1 Protease Inhibitors with High in Vivo Efficacy

1st Alpine Winter Conference on Medicinal and Synthetic Chemistry

Confirmed Speakers



Jean QUANCARD
(NOVARTIS, Basel, Switzerland)

OC11 - Discovery of a Ketohexokinase Inhibitor for the Treatment of Nafld/Nash: Fragment-to-Candidate via Structure-Based Drug Design and Parallel Chemistry



Brian RAYMER
(PFIZER, Cambridge, United States)